510(k) device
Optax System
Optax Systems, Inc. · Recorder, Attention Task Performance (LQD, Unclassified) · First FDA decision Jun 10, 2002, newest Jun 10, 2002ADHD
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
1
Naming "Optax"
MAUDE reports
0
Brand "Optax", since 2015
PubMed studies
5
Mentioning "Optax"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Optax System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- OPTAX SYSTEM510(k)
K020800 · Decided Jun 10, 2002 · 90 days after receipt
Device type: Recorder, Attention Task Performance (LQD) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Optax", any status and sponsor, newest update first.
- Effectiveness of the Quotient® ADHD Assessment in a System of CarePivotal-lookingTerminated
Kaiser PermanenteAcademic, hospital or other
NCT02094612 · 207 participants · Start Mar 2014 · Primary completion Aug 2015
Device: Quotient® · For: Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder With Hyperactivity
Sites: Folsom, California; Roseville, California; Walnut Creek, California
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Optax", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code LQD
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Optax"[tiab]. The summary above synthesizes these.
- Representation Meets Optimization: Training PINNs and PIKANs for Gray-Box Discovery in Systems Pharmacology.
Daryakenari NA, Shukla K, Karniadakis GE · ArXiv · 2025Preprint
- Twin study on heritability of activity, attention, and impulsivity as assessed by objective measures.
Heiser P, Heinzel-Gutenbrunner M, Frey J, et al. · J Atten Disord · 2006Comparative Study, Research Support, Non-U.S. Gov't
- Objective measurement of hyperactivity, impulsivity, and inattention in children with hyperkinetic disorders before and after treatment with methylphenidate.
Heiser P, Frey J, Smidt J, et al. · Eur Child Adolesc Psychiatry · 2004Clinical Trial
- Representation meets optimization: Training PINNs and PIKANs for gray-box discovery in systems pharmacology.
Ahmadi Daryakenari N, Shukla K, Karniadakis GE · Comput Biol Med · 2026
- Is OPTAx useful for monitoring the effect of stimulants on hyperactivity and inattention? A brief report.
Tabori-Kraft J, Sørensen MJ, Kaergaard M, et al. · Eur Child Adolesc Psychiatry · 2007
Other devices of this type
Also filed under product code LQD.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.